Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.87 USD 1.1% Market Closed
Market Cap: 119.4B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bristol-Myers Squibb Co
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Minority Interest
$58m
CAGR 3-Years
-7%
CAGR 5-Years
-11%
CAGR 10-Years
0%
Johnson & Johnson
NYSE:JNJ
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Minority Interest
$275m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Minority Interest
$58m
CAGR 3-Years
-6%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Zoetis Inc
NYSE:ZTS
Minority Interest
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Minority Interest
$80.7m
CAGR 3-Years
-26%
CAGR 5-Years
0%
CAGR 10-Years
20%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119.4B USD
Industry
Pharmaceuticals

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
71 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Minority Interest?
Minority Interest
58m USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Minority Interest amounts to 58m USD.

What is Bristol-Myers Squibb Co's Minority Interest growth rate?
Minority Interest CAGR 10Y
0%

Over the last year, the Minority Interest growth was -9%. The average annual Minority Interest growth rates for Bristol-Myers Squibb Co have been -7% over the past three years , -11% over the past five years .

Back to Top